Study of Intravenous (I.V.) Iclaprim Versus Linezolid in Complicated Skin and Skin Structure Infections [cSSSI] (ASSIST-2)

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The study is now completed

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Arpida AG
• Treatments: Iclaprim; Linezolid

Criteria

Inclusion Criteria:

• Diagnosis of an infection consistent with complicated skin and skin structure infection due to a gram positive pathogen.

Exclusion Criteria:

• Known or suspected hypersensitivity to any study medication or other related anti-infective medication

• Any known or suspected condition or concurrent treatment contraindicated by the prescribing information

• Previous enrollment in this study

• Treatment with any investigational drug within 30 days before enrollment